[A21-70] Carfilzomib (multiple myeloma) - Addendum to Commission A21-08
Last updated 15.07.2021
Project no.:
A21-70
Commission:
Commission awarded on 25.05.2021 by the Federal Joint Committee (G-BA).
Report type:
Addendum
Status:
Commission completed
Department/Division:
Drug Assessment
Application field:
Cancer
Indication:
Adult patients with multiple myeloma who have received at least one prior therapy
Result of dossier assessment:
Added benefit not proven.
Note:
If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.
| Project no. | Title | Status |
|---|---|---|
| A21-08 | Carfilzomib (multiple myeloma) - Benefit assessment according to §35a Social Code Book V | Commission completed |
Federal Joint Committee (G-BA)
2021.07.15 A G-BA decision was published.